Pharmanutra S.p.A. Stock

Equities

PHN

IT0005274094

Pharmaceuticals

Market Closed - Borsa Italiana 11:44:59 2024-05-21 am EDT 5-day change 1st Jan Change
48.25 EUR 0.00% Intraday chart for Pharmanutra S.p.A. +3.76% -14.45%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 113M 123M Sales 2025 * 129M 140M Capitalization 464M 504M
Net income 2024 * 17M 18.46M Net income 2025 * 20M 21.72M EV / Sales 2024 * 4.05 x
Net cash position 2024 * 6.13M 6.66M Net cash position 2025 * 16.73M 18.17M EV / Sales 2025 * 3.46 x
P/E ratio 2024 *
27 x
P/E ratio 2025 *
22.6 x
Employees 105
Yield 2024 *
1.83%
Yield 2025 *
2.06%
Free-Float 34.33%
More Fundamentals * Assessed data
Dynamic Chart
1 week+3.76%
Current month-9.64%
1 month-6.85%
3 months-21.16%
6 months-8.44%
Current year-14.45%
More quotes
1 week
47.25
Extreme 47.25
49.50
1 month
46.35
Extreme 46.35
54.00
Current year
46.35
Extreme 46.35
63.50
1 year
43.55
Extreme 43.55
63.50
3 years
35.30
Extreme 35.3
80.00
5 years
16.65
Extreme 16.65
80.00
10 years
12.00
Extreme 12
80.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-12-31
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 08-12-31
Members of the board TitleAgeSince
Director/Board Member 52 20-08-31
Chief Executive Officer - 02-12-31
Chief Operating Officer - 08-12-31
More insiders
Date Price Change Volume
24-05-21 48.25 0.00% 4,589
24-05-20 48.25 +0.52% 7,440
24-05-17 48 -0.52% 8,909
24-05-16 48.25 +1.47% 12,798
24-05-15 47.55 +2.26% 20,363

Real-time Borsa Italiana, May 21, 2024 at 11:44 am EDT

More quotes
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
48.25 EUR
Average target price
80.33 EUR
Spread / Average Target
+66.49%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW